Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APTURA I: Tyenne vs RoActemra in Rheumatoid Arthritis
NCT04512001Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Countries
- 9
01
Overview
A Phase 3 trial of leuprorelin extended-release injection in rheumatoid arthritis (RA), sponsored by Fresenius Kabi. Started Aug 2020; status: completed.
02
Drugs
leuprorelin extended-release injection
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04512001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512001.